Search results
Sep 26, 2022 · Professor of Medicine, University of Paris. Dr. Leboulch is a Professor of Medicine (emeritus-active) at the University of Paris-Saclay and at Harvard Medical School, where he remains as a Harvard Medical School Corresponding Faculty Member.
Apr 18, 2018 · In the beta thalassemia trial, the successful introduction of the modified globin gene was made possible by a vector, or delivery system, that Philippe Leboulch, one of the co-authors of the...
Philippe Leboulch's 197 research works with 14,252 citations and 32,448 reads, including: lovo‐cel gene therapy for Sickle Cell Disease: Treatment process evolution and outcomes in the...
Jan 24, 2022 · The LentiGlobin vector HPV569 and its derivative BB305 (ref. 14) were designed by Leboulch et al. to inhibit HbS polymerization while allowing in-patient quantification of vector-encoded ...
Sep 23, 2005 · Dr. Philippe Leboulch, a highly regarded professor and researcher at Harvard Medical School and Brigham and Women’s Hospital in Boston, will give a talk at The University of Texas at Dallas (UTD) on Friday, Sept. 30, about the possibility of gene therapy cures for sickle cell disease.
Apr 18, 2018 · As a postdoctoral fellow at Massachusetts Institute of Technology, Leboulch began researching a therapeutic approach to compensate for the genetic mutations that lead to both sickle-cell disease and beta-thalassemia.
Dec 11, 2009 · In June 2007, when the patient was 19 years old, Leboulch's team removed some of his bone marrow cells and treated them with a modified HIV virus, or lentivirus, carrying a good copy of the β-globin gene.
